Literature DB >> 10807560

Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics.

F Y Bois1.   

Abstract

A physiologically based pharmacokinetic model for trichloroethylene (TCE) in rodents and humans was calibrated with published toxicokinetic data sets. A Bayesian statistical framework was used to combine previous information about the model parameters with the data likelihood, to yield posterior parameter distributions. The use of the hierarchical statistical model yielded estimates of both variability between experimental groups and uncertainty in TCE toxicokinetics. After adjustment of the model by Markov chain Monte Carlo sampling, estimates of variability for the animal or human metabolic parameters ranged from a factor of 1.5-2 (geometric standard deviation [GSD]). Uncertainty was of the same order as variability for animals and higher than variability for humans. The model was used to make posterior predictions for several measures of cancer risk. These predictions were affected by both uncertainties and variability and exhibited GSDs ranging from 2 to 6 in mice and rats and from 2 to 10 for humans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807560      PMCID: PMC1637757          DOI: 10.1289/ehp.00108s2307

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  30 in total

1.  Development of new technique for risk assessment using physiologically based toxicokinetic models.

Authors:  G Johanson; F Jonsson; F Bois
Journal:  Am J Ind Med       Date:  1999-09       Impact factor: 2.214

2.  Pharmacokinetics of trichloroethylene in volunteers, influence of workload and exposure concentration.

Authors:  A C Monster; G Boersma; W C Duba
Journal:  Int Arch Occup Environ Health       Date:  1976-12-15       Impact factor: 3.015

3.  Exposure to trichloroethylene monitored by analysis of metabolites in blood and urine.

Authors:  O Vesterberg; I Astrand
Journal:  J Occup Med       Date:  1976-04

4.  Metabolism of trichloroethylene in man. II. Pharmacokinetics of metabolites.

Authors:  G Müller; M Spassovski; D Henschler
Journal:  Arch Toxicol       Date:  1974       Impact factor: 5.153

5.  Control of industrial exposure to tetrachloroethylene by measuring alveolar concentrations: theoretical approach using a mathematical model.

Authors:  E Guberan; J Fernandez
Journal:  Br J Ind Med       Date:  1974-04

6.  Urinary excretion of total trichloro-compounds, trichloroethanol, and trichloroacetic acid as a measure of exposure to trichloroethylene and tetrachloroethylene.

Authors:  M Ikeda; H Otsuji; T Imamura; Y Komoike
Journal:  Br J Ind Med       Date:  1972-07

7.  Experimental human exposure to trichloroethylene.

Authors:  R D Stewart; H C Dodd; H H Gay; D S Erley
Journal:  Arch Environ Health       Date:  1970-01

8.  Exposure to trichloroethylene I. Uptake and distribution in man.

Authors:  I Astrand; P Ovrum
Journal:  Scand J Work Environ Health       Date:  1976-12       Impact factor: 5.024

9.  Metabolism of trichloroethylene in man. III. Interaction of trichloroethylene and ethanol.

Authors:  G Müller; M Spassowski; D Henschler
Journal:  Arch Toxicol       Date:  1975       Impact factor: 5.153

10.  Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics.

Authors:  F Y Bois
Journal:  Environ Health Perspect       Date:  2000-05       Impact factor: 9.031

View more
  19 in total

Review 1.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.

Authors:  Ivelina Gueorguieva; Leon Aarons; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-29       Impact factor: 2.745

3.  Impact of Nonalcoholic Fatty Liver Disease on Toxicokinetics of Tetrachloroethylene in Mice.

Authors:  Joseph A Cichocki; Shinji Furuya; Kranti Konganti; Yu-Syuan Luo; Thomas J McDonald; Yasuhiro Iwata; Weihsueh A Chiu; David W Threadgill; Igor P Pogribny; Ivan Rusyn
Journal:  J Pharmacol Exp Ther       Date:  2017-02-01       Impact factor: 4.030

Review 4.  Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Authors:  Nikolaos Tsamandouras; Amin Rostami-Hodjegan; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

5.  A physiologically based pharmacokinetic model of rifampin in mice.

Authors:  Michael A Lyons; Brad Reisfeld; Raymond S H Yang; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

6.  PBPK modeling of impact of nonalcoholic fatty liver disease on toxicokinetics of perchloroethylene in mice.

Authors:  Chimeddulam Dalaijamts; Joseph A Cichocki; Yu-Syuan Luo; Ivan Rusyn; Weihsueh A Chiu
Journal:  Toxicol Appl Pharmacol       Date:  2020-05-21       Impact factor: 4.219

7.  Evaluation and calibration of high-throughput predictions of chemical distribution to tissues.

Authors:  Robert G Pearce; R Woodrow Setzer; Jimena L Davis; John F Wambaugh
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-10-14       Impact factor: 2.745

8.  Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.

Authors:  Michael A Lyons
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

9.  Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine.

Authors:  Sungkyoon Kim; David Kim; Gary M Pollack; Leonard B Collins; Ivan Rusyn
Journal:  Toxicol Appl Pharmacol       Date:  2009-05-03       Impact factor: 4.219

10.  A Bayesian population PBPK model for multiroute chloroform exposure.

Authors:  Yuching Yang; Xu Xu; Panos G Georgopoulos
Journal:  J Expo Sci Environ Epidemiol       Date:  2009-05-27       Impact factor: 5.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.